SAN DIEGO, Jan. 12, 2024 /PRNewswire/ -- Halozyme
Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced that
it will host an Investor Business Forum and Long-Term Outlook Call
on Wednesday, January 17, 2024 at
5:30 a.m. PT / 8:30 a.m. ET.
On the call, Dr. Helen Torley,
President and Chief Executive Officer will be joined by
Mark Snyder, Chief Legal Officer and
Nicole LaBrosse, Chief Financial
Officer to present detailed guidance around the patent dynamics
that are expected to drive revenue durability of Halozyme's
ENHANZE® drug delivery technology. The company will also
provide 2024 financial guidance as well as long term financial
outlook.
A webcast of the live call can be accessed via link here:
https://ow.ly/Zi0050QqaCF. The call will also be webcast live
through the "Investors" section of Halozyme's corporate website and
a recording will be made available following the close of the call.
To access the webcast and presentation materials related to the
call, please visit Halozyme.com.
The conference call may also be accessed with the dial-in
information below:
Participant Toll-Free Number: 800-225-9448
Participant Direct/International Number: 203-518-9708
Conference ID: HALO0117
About Halozyme
Halozyme is a biopharmaceutical company bringing disruptive
solutions to significantly improve patient experiences and outcomes
for emerging and established therapies. As the innovators of the
ENHANZE® technology with the proprietary enzyme rHuPH20, Halozyme's
commercially-validated solution is used to facilitate the delivery
of injected drugs and fluids in order to reduce the treatment
burden to patients. Having touched more than 800,000 patient lives
in post-marketing use in seven commercialized products across more
than 100 global markets, Halozyme has licensed its ENHANZE®
technology to leading pharmaceutical and biotechnology companies
including Roche, Takeda, Pfizer, AbbVie, Eli Lilly, Bristol Myers
Squibb, Alexion, argenx, Horizon Therapeutics, ViiV Healthcare,
Chugai Pharmaceutical and Acumen Pharmaceuticals.
Halozyme also develops, manufactures and commercializes, for
itself or with partners, drug-device combination products using its
advanced auto-injector technology that are designed to provide
commercial or functional advantages such as improved convenience
and tolerability, and enhanced patient comfort and adherence. The
Company has a commercial portfolio of proprietary products
including Hylenex® and XYOSTED® and partnered commercial products
and ongoing product development programs with several
pharmaceutical companies including Teva Pharmaceuticals and Idorsia
Pharmaceuticals.
Halozyme is headquartered in San
Diego, CA and has offices in Ewing, NJ and Minnetonka, MN. Minnetonka is also the site of its operations
facility.
For more information visit www.halozyme.com and connect with us
on LinkedIn and Twitter.
Contacts:
Tram Bui
VP, Investor Relations and Corporate Communications
609-359-3016
tbui@halozyme.com
Samantha Gaspar
Teneo
617-877-9710
samantha.gaspar@teneo.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/halozyme-to-host-investor-business-forum-and-long-term-outlook-call-302033655.html
SOURCE Halozyme Therapeutics, Inc.